Venetoclax-地塞米松对比Pomalidomide-地塞米松治疗t(11;14)阳性复发难治多发性骨髓瘤:III期CANOVA研究主要结果
CANOVA是一项随机、开放标签、III期研究,纳入既往接受≥2线治疗的t(11;14)阳性复发难治多发性骨髓瘤成人患者263例,1:1随机接受venetoclax-地塞米松或pomalidomide-地塞米松治疗。总缓解率和MRD阴性率在venetoclax-地塞米松组更高,但总生存期无统计学差异。
要点
- 主要终点PFS未达到统计学显著差异,venetoclax-地塞米松组中位PFS 9.9个月对比5.8个月(HR 0.823)。
- venetoclax-地塞米松组总缓解率62%、≥非常好的部分缓解率39%,均高于对照组。
- venetoclax-地塞米松组≥3级治疗中出现不良事件发生率67%,低于对照组的83%。
核心结论
- 主要终点PFS未达到,venetoclax-地塞米松组PFS和OS在数值上长于pomalidomide-地塞米松组。
- 与既往研究一致,venetoclax-地塞米松与感染相关,未观察到新的安全性信号。
研究设计与样本
- 随机、开放标签、III期CANOVA研究(NCT03539744),纳入既往接受≥2线治疗的t(11;14)阳性复发难治多发性骨髓瘤成人患者。
- 共263例患者1:1随机分配至venetoclax-地塞米松组(n=133)或pomalidomide-地塞米松组(n=130),治疗至疾病进展或不可耐受毒性。
主要发现
- 总缓解率62% vs 35%,≥非常好的部分缓解率39% vs 14%,MRD阴性率(<10^-5)8% vs 0%。
- 中位OS:venetoclax-地塞米松组32.4个月(95%CI 26.4–40.7),pomalidomide-地塞米松组26.9个月(95%CI 20.4–38.9),HR 0.856(95%CI 0.612–1.197)。
- ≥3级治疗中出现不良事件发生率67% vs 83%;治疗中出现死亡16例(12%)vs 8例(6%)。
关键数值与推荐
- MRD阴性率(<10^-5):venetoclax-地塞米松组8%,pomalidomide-地塞米松组0%。
临床怎么用
- 对于t(11;14)阳性复发难治多发性骨髓瘤,venetoclax-地塞米松在缓解率和MRD阴性率上优于pomalidomide-地塞米松,但PFS未达统计学显著。
- venetoclax-地塞米松组≥3级不良事件发生率较低,但治疗中出现死亡比例较高,需关注感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Venetoclax, an oral BCL-2 inhibitor, has efficacy in t(11;14)-positive relapsed/refractory multiple myeloma (RRMM), which is enhanced by dexamethasone, which promotes BCL-2 dependency. METHODS: The randomized, open-label, phase III CANOVA study (ClinicalTrials.gov identifier: NCT03539744) enrolled adults with t(11;14)-positive RRMM who had received ≥2 previous lines of therapy. Patients were randomly assigned (1:1) to venetoclax-dexamethasone or pomalidomide-dexamethasone until progression or intolerable toxicity. The primary end point was independent review committee assessed-progression-free survival (PFS) in the intention-to-treat population analyzed by stratified log-rank test (two-sided type I error rate, α = .05), with hazard ratio (HR) and 95% CI estimated by stratified Cox proportional hazard model. Secondary end points included response rates, overall survival (OS), minimal residual disease (MRD) negativity rate (<10-5), and safety. RESULTS: Overall, 263 patients were randomly assigned (venetoclax-dexamethasone, n = 133; pomalidomide-dexamethasone, n = 130). Median PFS was 9.9 months (95% CI, 6.9 to 12.6) with venetoclax-dexamethasone versus 5.8 months (95% CI, 3.8 to 9.2) with pomalidomide-dexamethasone (HR, 0.823 [95% CI, 0.596 to 1.136]; P = .24). Overall response and very good partial response or better rates were 62% and 39%, respectively, with venetoclax-dexamethasone versus 35% and 14% with pomalidomide-dexamethasone. MRD negativity rate was 8% with venetoclax-dexamethasone and 0% with pomalidomide-dexamethasone. Median OS was 32.4 months (95% CI, 26.4 to 40.7) with venetoclax-dexamethasone and 26.9 months (95% CI, 20.4 to 38.9) with pomalidomide-dexamethasone (HR, 0.856 [95% CI, 0.612 to 1.197]). Grade ≥3 treatment-emergent adverse event rates were 67% with venetoclax-dexamethasone versus 83% with pomalidomide-dexamethasone. There were 16 (12%) treatment-emergent deaths with venetoclax-dexamethasone versus 8 (6%) with pomalidomide-dexamethasone. CONCLUSION: The primary end point of PFS was not met. PFS and OS were numerically longer with venetoclax-dexamethasone versus pomalidomide-dexamethasone in t(11;14)-positive RRMM. Consistent with previous studies, infections were associated with venetoclax-dexamethasone; no new safety signals were observed.
引用
- Popat R, Beksac M, Dimopoulos MA, et al. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. J Clin Oncol. 2025. PMID: 41370738. doi:10.1200/JCO-25-00924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。